



November
2014
Volume 9
Issue 11
Follow us:



Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington Disease Trial

Business Wire, November 4, 2014

Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington disease. Currently, there are no approved therapies available for the treatment of Huntington disease, beyond symptom management.

“Teva prides itself in striving to help patients with neurodegenerative diseases through research and innovation,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries, Ltd. “Laquinimod has been shown to modulate several significant pathways common to key neurodegenerative disease. More specifically, it modulates the immune cell lineages in the periphery and in the CNS. We look forward to the results from both of these studies.” For the full story, click [here](#).

National Population Health Study of Neurological Conditions

Neurological Health Charities Canada

Neurological Health Charities Canada (NHCC) collaborated with the Public Health Agency of Canada to lead the first-ever National Population Study of Neurological Conditions (NPHSNC). The NPHSNC was a 4-year project (2009-2013) funded by a \$15 million investment from the Government of Canada. The study sought to learn more about the experiences of people impacted by neurological conditions and to address the lack of information related to neurological conditions in Canada. To learn more, click [here](#).

THE LATEST FROM HDBUZZ

Huntington disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

HDBuzz, November 4, 2014

A new clinical trial just announced for 2015 aims to test a “huntingtin lowering” therapy, called an antisense oligonucleotide (ASO), that attacks mutant huntingtin directly. It’s the first-ever human HD trial to fight HD at the root of the problem, and has shown great promise in animal models. Click [here](#) for the full article.

Should we worry about a huntingtin invasion?

HDBuzz, October 27, 2014

New work in brain diseases like Alzheimer’s suggests that brain cells called neurons might be ‘catching’ the sickness from their neighbors. A recently published paper suggests that, in very specific lab conditions, this might also happen in Huntington disease. What does this mean for what we know about HD, and how to treat it? Click [here](#) for the full article.

AMARYLLIS PHOTO FESTIVAL
Submit your favourite Amaryllis photo to amaryllis@huntingtonsociety.ca for a chance to feature your photo on the Amaryllis banner on the HSC website!

10th Annual CHDI HD Therapeutics Conference

SAVE THE DATE!

February 23-26, 2015
The Parker Hotel
Palm Springs, California

Registration is now open

The Huntington Society of Canada is a proud supporter of

HUNTINGTON'S DISEASE YOUTH ORGANIZATION

YOUTH MENTORSHIP PROGRAM

For more information about the program and how to become a mentor or mentee, please contact the Youth Mentorship Coordinator:
mentorship@huntingtonsociety.ca
1-306-979-9111 OR
Toll Free 1-855-253-0215

HD research news.
In plain language.
Written by scientists.
For the global HD community.
HDBuzz.net

UPCOMING HSC EVENTS

There are a lot of exciting events coming up. Visit our website to see what is happening in your area!

For upcoming events visit
www.huntingtonsociety.ca/events/